Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,167
Recruiting: 1,126
Ph III recruiting: 114
Growth YoY: +4%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.4 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,291)

clinicaltrialsPublishedShowing 551–600 of 3,875 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04505254	Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia	active not recruiting	Phase 2	60	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials
NCT04566887	Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma	active not recruiting	Phase 2	105	University Health Network, TorontoOTHER	1	Jun 12, 2026	clinicaltrials